Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.

Koch A, Pizzichini E, Hamilton A, Hart L, Korducki L, De Salvo MC, Paggiaro P.

Int J Chron Obstruct Pulmon Dis. 2014 Jul 5;9:697-714. doi: 10.2147/COPD.S62502. eCollection 2014.

PMID:
25045258
[PubMed - in process]
Free PMC Article
2.

Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.

Ferguson GT, Feldman GJ, Hofbauer P, Hamilton A, Allen L, Korducki L, Sachs P.

Int J Chron Obstruct Pulmon Dis. 2014 Jun 16;9:629-45. doi: 10.2147/COPD.S61717. eCollection 2014.

PMID:
24966672
[PubMed - in process]
Free PMC Article
3.

Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.

ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R.

Int J Chron Obstruct Pulmon Dis. 2014 Oct 14;9:1133-44. doi: 10.2147/COPD.S72482. eCollection 2014.

PMID:
25342898
[PubMed - in process]
Free PMC Article
4.

The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies.

Feldman GJ, Bernstein JA, Hamilton A, Nivens MC, Korducki L, LaForce C.

Springerplus. 2014 Aug 9;3:419. doi: 10.1186/2193-1801-3-419. eCollection 2014.

PMID:
25187881
[PubMed]
Free PMC Article
5.

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

Keam SJ, Keating GM.

Treat Respir Med. 2004;3(4):247-68. Review.

PMID:
15350163
[PubMed - indexed for MEDLINE]
6.

Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial.

Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, Goldman M.

Drugs. 2008;68(14):1975-2000.

PMID:
18778120
[PubMed - indexed for MEDLINE]
7.

Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.

Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.

Clin Ther. 2011 Dec;33(12):1974-84. doi: 10.1016/j.clinthera.2011.11.009.

PMID:
22177371
[PubMed - indexed for MEDLINE]
8.

Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.

Hanania NA, Boota A, Kerwin E, Tomlinson L, Denis-Mize K.

Drugs. 2009 Jun 18;69(9):1205-16. doi: 10.2165/00003495-200969090-00005.

PMID:
19537837
[PubMed - indexed for MEDLINE]
9.

Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.

Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Gates D, Staudinger H.

Int J Chron Obstruct Pulmon Dis. 2012;7:73-86. doi: 10.2147/COPD.S29444. Epub 2012 Feb 3.

PMID:
22334770
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma.

Beeh KM, Moroni-Zentgraf P, Ablinger O, Hollaenderova Z, Unseld A, Engel M, Korn S.

Respir Res. 2014 Jun 3;15:61. doi: 10.1186/1465-9921-15-61.

PMID:
24890738
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Long-acting beta2-agonists for chronic obstructive pulmonary disease.

Kew KM, Mavergames C, Walters JA.

Cochrane Database Syst Rev. 2013 Oct 15;10:CD010177. doi: 10.1002/14651858.CD010177.pub2. Review.

PMID:
24127118
[PubMed - indexed for MEDLINE]
12.

Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial.

Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, Silkoff PE.

Drugs. 2009;69(5):549-65. doi: 10.2165/00003495-200969050-00004.

PMID:
19368417
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.

Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B; INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators.

Thorax. 2010 Jun;65(6):473-9. doi: 10.1136/thx.2009.125435.

PMID:
20522841
[PubMed - indexed for MEDLINE]
14.

Efficacy and safety of inhaled formoterol 4.5 and 9 μg twice daily in Japanese and European COPD patients: phase III study results.

Bogdan MA, Aizawa H, Fukuchi Y, Mishima M, Nishimura M, Ichinose M.

BMC Pulm Med. 2011 Nov 15;11:51. doi: 10.1186/1471-2466-11-51.

PMID:
22085439
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial.

D'Urzo A, Ferguson GT, van Noord JA, Hirata K, Martin C, Horton R, Lu Y, Banerji D, Overend T.

Respir Res. 2011 Dec 7;12:156. doi: 10.1186/1465-9921-12-156.

PMID:
22151296
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol.

Roskell NS, Anzueto A, Hamilton A, Disse B, Becker K.

Int J Chron Obstruct Pulmon Dis. 2014 Jul 31;9:813-24. doi: 10.2147/COPD.S59673. eCollection 2014.

PMID:
25114521
[PubMed - in process]
Free PMC Article
17.

24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD.

van Noord JA, Smeets JJ, Drenth BM, Rascher J, Pivovarova A, Hamilton AL, Cornelissen PJ.

Pulm Pharmacol Ther. 2011 Dec;24(6):666-72. doi: 10.1016/j.pupt.2011.07.006. Epub 2011 Aug 6.

PMID:
21839850
[PubMed - indexed for MEDLINE]
18.

Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.

Doherty DE, Tashkin DP, Kerwin E, Knorr BA, Shekar T, Banerjee S, Staudinger H.

Int J Chron Obstruct Pulmon Dis. 2012;7:57-71. doi: 10.2147/COPD.S27320. Epub 2012 Feb 3.

PMID:
22334769
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial.

Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Banerjee S, Staudinger H.

Int J Chron Obstruct Pulmon Dis. 2012;7:43-55. doi: 10.2147/COPD.S27319. Epub 2012 Feb 3. Erratum in: Int J Chron Obstruct Pulmon Dis. 2012;7:765.

PMID:
22334768
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis.

Cope S, Zhang J, Williams J, Jansen JP.

BMC Pulm Med. 2012 Jun 25;12:29. doi: 10.1186/1471-2466-12-29.

PMID:
22732017
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk